Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer.
Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer.
Hematology Am Soc Hematol Educ Program. 2016 Dec 02;2016(1):206-207
Authors: Kreuziger LB, Streiff M
Abstract
A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL, with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?
PMID: 27913481 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Education | Hematology | Prostate Cancer | Pulmonary Thromboembolism | Thrombosis | Universities & Medical Training